The document discusses the personal genetic testing company 23andMe. It provides an overview of 23andMe's $99 genetic profile product, how it works using microarray technology rather than full genome sequencing, its revenue model and funding history. The document also summarizes 23andMe's competitive advantages in scale and personalized displays, growth in new users, and predicts its continued success as costs decrease over time.